Is complementary and alternative medicine (CAM) cost-effective? A systematic review

被引:110
作者
Herman P.M. [1 ]
Craig B.M. [2 ]
Caspi O. [3 ]
机构
[1] Program in Integrative Medicine, University of Arizona, Tucson, AZ
[2] Department of Pharmacy, University of Arizona, Tucson, AZ
[3] Recanati Center for Internal Medicine and Research, Rabin Medical Center, Petah Tikva, Beilinson Campus
来源
BMC Complementary and Alternative Medicine | / 5卷 / 1期
关键词
Economic Evaluation; Manual Therapy; Conventional Care; Spinal Manipulative Therapy; Humanistic Outcome;
D O I
10.1186/1472-6882-5-11
中图分类号
学科分类号
摘要
Background: Out-of-pocket expenditures of over $34 billion per year in the US are an apparent testament to a widely held belief that complementary and alternative medicine (CAM) therapies have benefits that outweigh their costs. However, regardless of public opinion, there is often little more than anecdotal evidence on the health and economic implications of CAM therapies. The objectives of this study are to present an overview of economic evaluation and to expand upon a previous review to examine the current scope and quality of CAM economic evaluations. Methods: The data sources used were Medline, AMED, Alt-HealthWatch, and the Complementary and Alternative Medicine Citation Index; January 1999 to October 2004. Papers that reported original data on specific CAM therapies from any form of standard economic analysis were included. Full economic evaluations were subjected to two types of quality review. The first was a 35-item checklist for reporting quality, and the second was a set of four criteria for study quality (randomization, prospective collection of economic data, comparison to usual care, and no blinding). Results: A total of 56 economic evaluations (39 full evaluations) of CAM were found covering a range of therapies applied to a variety of conditions. The reporting quality of the full evaluations was poor for certain items, but was comparable to the quality found by systematic reviews of economic evaluations in conventional medicine. Regarding study quality, 14 (36%) studies were found to meet all four criteria. These exemplary studies indicate CAM therapies that may be considered cost-effective compared to usual care for various conditions: acupuncture for migraine, manual therapy for neck pain, spa therapy for Parkinson's, self-administered stress management for cancer patients undergoing chemotherapy, pre- and post-operative oral nutritional supplementation for lower gastrointestinal tract surgery, biofeedback for patients with "functional" disorders (eg, irritable bowel syndrome), and guided imagery, relaxation therapy, and potassium-rich diet for cardiac patients. Conclusion: Whereas the number and quality of economic evaluations of CAM have increased in recent years and more CAM therapies have been shown to be of good value, the majority of CAM therapies still remain to be evaluated. © 2005 Herman et al., licensee BioMed Central Ltd.
引用
收藏
页数:15
相关论文
共 100 条
[1]  
White A.R., Resch K.L., Ernst E., Methods of economic evaluation in complementary medicine, Forsch. Komplementarmed., 3, pp. 196-203, (1996)
[2]  
MacLennan A.H., Wilson D.H., Taylor A.W., The escalating cost and prevalence of alternative medicine, Preventive Medicine, 35, pp. 166-173, (2002)
[3]  
Eisenberg D.M., Davis R.B., Ettner S.L., Appel S., Wilkey S., Van Rompay M., Kessler R.C., Trends in alternative medicine use in the United States, 1990-1997, JAMA, 280, pp. 1515-1569, (1998)
[4]  
White A.R., Ernst E., Economic analysis of complementary medicine: A systematic review, Complementary Therapies in Medicine, 8, pp. 111-118, (2000)
[5]  
Pelletier K.R., Astin J.A., Integration and reimbursement of complementary and alternative medicine by managed care and insurance providers: 2000 update and cohort analysis, Alternative Therapies, 8, pp. 38-48, (2002)
[6]  
Neumann P.J., Evidence-based and value-based formulary guidelines, Health Affairs, 23, pp. 124-134, (2004)
[7]  
Sullivan S.D., Lyles A., Luce B., Grigar J., AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in US health plans and pharmacy benefits management organizations, Journal of Managed Care Pharmacy, 7, pp. 272-282, (2001)
[8]  
Claxton K., Neumann P.J., Araki S., Weinstein M.C., Bayesian value-of-information analysis: An application to a policy model of Alzheimer's disease, International Journal of Technology Assessment in Health Care, 17, pp. 38-55, (2001)
[9]  
Claxton K., Posnett J., An economic approach to clinical trial design and research priority-setting, Medical Economics, 5, pp. 513-524, (1996)
[10]  
Drummond M.F., O'Brien B., Stoddart G.L., Torrance G.W., Methods for the Economic Evaluation of Health Care Programmes, (1997)